2026.11.09
“A Deeply Trusted Partner” | Apeloa Receives Recognition from International Innovative Biotech Company, Further Demonstrating Its CDMO Capabilities
2026.10.22
Peking University and Apeloa Pharmaceutical Co., Ltd. Establish Joint Laboratory for Nucleic Acid Drugs and Biomanufacturing
2026.10.19
Apeloa Pharmaceutical Hosts 2026 SAB Annual Meeting & International Forum on Frontiers in Chemistry and Biopharmaceutical Innovation in Hengdian
2026.10.16
Apeloa's Gas API CDMO Project Becomes China's First to Pass U.S. FDA On-Site Inspection
2026.10.14
Apeloa Pharmaceutical Wins 2026 Service Excellence Award from Leading Global Pharma Partner
2026.10.09
Apeloa Pharmaceutical Secures NMPA Approval for Deutenzalutamide API, Expanding Its CDMO Capabilities Across the Innovative Drug Value Chain
2026.10.08
Apeloa Showcases Integrated Pharmaceutical Solutions at CPHI Milan 2026
2026.09.24
Apeloa Showcases Global CDMO Capabilities at Three Major U.S. and European Industry Events
2025.10.29
Apeloa appoints leading scientists to advisory board, prioritizing pharma innovation and development
2025.08.04
Apeloa showcases first-class CDMO services at CMC-China Pharma Expo
2025.07.02
Apeloa puts sustainability centre stage at US GC&E conference
2025.06.26
Apeloa underscores innovation and modernity at CPHI China 2025
